Literature DB >> 30089063

Adjuvant Pembrolizumab in Resected Stage III Melanoma.

Alexander M M Eggermont1,2, Caroline Robert1, Stefan Suciu3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30089063     DOI： 10.1056/NEJMc1807505

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Impact of Immunotherapy after Resection of Pancreatic Cancer.

Authors:  Thuy B Tran; Vijay K Maker; Ajay V Maker
Journal:  J Am Coll Surg       Date:  2019-02-10       Impact factor: 6.113

2.  Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Authors:  Jeffrey S Weber; Tayla Poretta; Brian D Stwalley; Leon A Sakkal; Ella X Du; Travis Wang; Yan Chen; Yan Wang; Keith A Betts; Alexander N Shoushtari
Journal:  Cancer Immunol Immunother       Date:  2022-10-05       Impact factor: 6.630

3.  Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety.

Authors:  Caroline A Nebhan; Douglas B Johnson
Journal:  Expert Rev Anticancer Ther       Date:  2021-02-14       Impact factor: 3.627

4.  Sentinel Lymph Node Biopsy Was Associated With Favorable Survival Outcomes For Patients With Clinically Node-Negative Asian Melanoma.

Authors:  John Wen-Cheng Chang; Yen-Lin Huang; Yao-Yu Chang; Yung-Feng Lo; Tsung-Ying Ho; Yi-Ting Huang; Huan-Wu Chen; Chiao-En Wu
Journal:  Cancer Manag Res       Date:  2019-11-14       Impact factor: 3.989

5.  Immune checkpoint inhibitors.

Authors:  Guido Kroemer; Laurence Zitvogel
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.